Lobbying Governance
Overall Assessment | Analysis | Score |
---|---|---|
Moderate |
Kissei Pharmaceutical has established limited processes to align its indirect external engagement on climate issues with its climate commitments, primarily through industry association participation, but it does not disclose a formal policy or dedicated oversight for its lobbying activities. The company reports that "当社は日本製薬工業協会(製薬協)の環境問題検討会(2022年4月発足)にメンバーとして参加しており、気候変動問題に対する課題検討や日本製薬団体連合会(日薬連)環境委員会への環境問題に関する製薬協の意見のとりまとめ等を行う", and that "検討会での内容については当社内のサステナビリティ推進委員会(旧SDGs推進委員会)においても情報共有し、社内での行動推進に繋げていく", demonstrating an internal committee reviewing and promoting actions based on association discussions. The company also notes its continued cooperation on the "日薬連カーボンニュートラル行動計画" through surveys, showing engagement at the indirect lobbying level. However, the company does not disclose any process for direct lobbying alignment, no named individual or formal governance body responsible for approving or reviewing lobbying positions, and states "No, and we do not plan to have one in the next two years" regarding a public commitment to align engagement with the Paris Agreement, indicating an absence of a comprehensive climate-lobbying governance framework.
View Sources
|
C |